Remove Bacteria Remove Bacterium Remove Protein
article thumbnail

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Pharmaceutical Technology

An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. It is compatible with standard-of-care antibiotics. Pivotal trials on LMN-201 are expected to commence in 2023.

Bacterium 130
article thumbnail

Valneva accelerates Lyme disease vaccine R&D project with Pfizer

pharmaphorum

This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists discover small RNA that regulates bacterial infection

The Pharma Data

Pseudomonas aeruginosa, a common environmental bacterium, can colonize different body parts, such as the lungs, leading to persistent, chronic infections that can last a lifetime – a common occurrence in people with cystic fibrosis. “Our study took a novel approach to look directly into the bacterium’s behavior in the human host.”

RNA 40
article thumbnail

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. GSK said it is paying $2.1

article thumbnail

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

pharmaphorum

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.

article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

Anthrax is a rare, yet severe disease caused by the bacterium B. The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. What Is Anthrax?

article thumbnail

New Research Shows IBS Symptoms May be Caused by Gut Infections

XTalks

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments). Moreover, the response did not induce symptoms typical of a food allergy.